4//SEC Filing
Welgus Howard G. 4
Accession 0001787306-25-000115
CIK 0001787306other
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 6:28 PM ET
Size
14.0 KB
Accession
0001787306-25-000115
Insider Transaction Report
Form 4
Welgus Howard G.
Director
Transactions
- Sale
Common Stock
2025-08-01$14.30/sh−6,110$87,362→ 100,206 total - Exercise/Conversion
Common Stock
2025-08-01+3,890→ 104,096 total - Exercise/Conversion
Common Stock
2025-08-01+6,110→ 106,316 total - Sale
Common Stock
2025-08-01$14.30/sh−3,890$55,620→ 100,206 total - Exercise/Conversion
Stock Option (right to buy)
2025-08-01−3,890→ 0 totalExercise: $1.68Exp: 2029-03-13→ Common Stock (3,890 underlying) - Exercise/Conversion
Stock Option (right to buy)
2025-08-01−6,110→ 0 totalExercise: $0.58Exp: 2028-06-13→ Common Stock (6,110 underlying)
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.
- [F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.14 to $14.55, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]This option is fully vested.
Documents
Issuer
Arcutis Biotherapeutics, Inc.
CIK 0001787306
Entity typeother
Related Parties
1- filerCIK 0001801050
Filing Metadata
- Form type
- 4
- Filed
- Aug 4, 8:00 PM ET
- Accepted
- Aug 5, 6:28 PM ET
- Size
- 14.0 KB